Fujifilm Diosynth Biotechnologies (Fujifilm), a contract development and manufacturing organisation (DCMO) has invested in Vanrx Pharmasystems’ SA25 Aseptic Filling Workcell gloveless isolator technology with automated environmental monitoring and no glass to glass contact.
The product purchase allows Fujifilm to extend its gene therapy and viral vaccine fill/finish capabilities to provide services in support of late phase candidates and commercial supply.
“Developers of advanced therapies need to be ready to move swiftly into commercial production, from bulk drug substance and into final dosage form,” said Gerry Farrell, Chief Operating Officer of FUJIFILM Diosynth Biotechnologies, Texas site. “We recognised that having Fill Finish capabilities that extend beyond the current clinical stage is essential to support the rapid delivery of clinical candidates to patients.”
Fujifilm’s fill/finish services offer rapid changeover between drug products and containers, production predictability and the ability to scale up to support commercial production, even when filling and stoppering complex drug products while minimising defect rates to maximise yield, which is of critical importance when filling very high-value products.
These extended Fill / Finish services will be provided from Fujifilm’s state of the art Flexible Biomanufacturing Facility located in College Station, Texas.